| 臺大學術典藏 |
2021-02-18T08:01:12Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; JA-DER LIANG; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-02-04T07:16:21Z |
Expression of the caudal-type homeodomain transcription factor CDX2 is related to clinical outcome in biliary tract carcinoma
|
YU-TING CHANG; Hsu C.; Jeng Y.-M.; Chang M.-C.; Wei S.-C.; Wong J.-M. |
| 臺大學術典藏 |
2021-02-04T02:48:52Z |
Study on the transient response to the point-to-point motion controls on a dual-axes air-bearing planar stage
|
Kuo, F.-C.;Hsu, C.;Hsieh, M.-R.;Yen, J.-Y.;Chen, L.-C.;Chung, T.-T.;Wang, F.-C.Jia-Yush Yen;Fu-Cheng Wang; Kuo, F.-C.; Hsu, C.; Hsieh, M.-R.; Yen, J.-Y.; Chen, L.-C.; Chung, T.-T.; Wang, F.-C.; JIA-YUSH YEN; FU-CHENG WANG |
| 臺大學術典藏 |
2021-02-02T02:48:01Z |
Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: A distinct entity with lower aggressiveness and higher chemosensitivity
|
Kuo S.-H.; Yeh K.-H.; Chen L.-T.; Lin C.-W.; PING-NING HSU; Hsu C.; Wu M.-S.; Tzeng Y.-S.; Tsai H.-J.; Wang H.-P.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-02T02:47:55Z |
Development of a PD-L1-expressing orthotopic liver cancer model: Implications for immunotherapy for hepatocellular carcinoma
|
Ou D.-L.; Lin Y.-Y.; Hsu C.-L.; Lin Y.-Y.; Chen C.-W.; Yu J.-S.; Miaw S.-C.; PING-NING HSU; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2021-02-02T02:21:24Z |
Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: A distinct entity with lower aggressiveness and higher chemosensitivity
|
Kuo S.-H.; Yeh K.-H.; Chen L.-T.; Lin C.-W.; Hsu P.-N.; Hsu C.; MING-SHIANG WU; Tzeng Y.-S.; Tsai H.-J.; Wang H.-P.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:07:01Z |
MVP (mitomycin-C, vinblastine, cisplatin) salvage chemotherapy for relapsed and refractory metastatic breast cancer
|
Hsu C.;Kun-Huei Yeh;Hong R.-L.;Yang C.-H.;Lin M.-T.;Chen Y.-C.;Cheng A.-L.; Hsu C.; KUN-HUEI YEH; Hong R.-L.; Yang C.-H.; Lin M.-T.; Chen Y.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:58Z |
Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL) - A very effective regimen with good patients' compliance for advanced gastric cancer
|
Cheng A.-L.; KUN-HUEI YEH; Lin J.-T.; Hsu C.; Liu M.-Y. |
| 臺大學術典藏 |
2021-01-28T01:06:52Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C.-H.;Cheng A.-L.;Hsu C.;Yang C.-H.;Lu Y.-S.;Lin C.-C.;Bu C.-F.;Kun-Huei Yeh; Hsu C.-H.; Cheng A.-L.; Hsu C.; Yang C.-H.; Lu Y.-S.; Lin C.-C.; Bu C.-F.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:50Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Lu Y.-S.;Hsu C.;Li C.-C.;Kuo S.-H.;Kun-Huei Yeh;Yang C.-H.;Hsu C.-H.;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Hsu C.; Li C.-C.; Kuo S.-H.; KUN-HUEI YEH; Yang C.-H.; Hsu C.-H.; Wu C.-Y.; Cheng A.-L. |
